IL311710A - Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome - Google Patents

Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome

Info

Publication number
IL311710A
IL311710A IL311710A IL31171024A IL311710A IL 311710 A IL311710 A IL 311710A IL 311710 A IL311710 A IL 311710A IL 31171024 A IL31171024 A IL 31171024A IL 311710 A IL311710 A IL 311710A
Authority
IL
Israel
Prior art keywords
cd40l
rheumatism
prevention
treatment
specific
Prior art date
Application number
IL311710A
Other languages
English (en)
Hebrew (he)
Inventor
Ilias Alevizos
Jorn Drappa
Gabor Illei
William Rees
Liangwei Wang
Original Assignee
Viela Bio Inc
Ilias Alevizos
Jorn Drappa
Gabor Illei
William Rees
Liangwei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc, Ilias Alevizos, Jorn Drappa, Gabor Illei, William Rees, Liangwei Wang filed Critical Viela Bio Inc
Publication of IL311710A publication Critical patent/IL311710A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
IL311710A 2021-09-28 2022-09-28 Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome IL311710A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249553P 2021-09-28 2021-09-28
US202263375282P 2022-09-12 2022-09-12
PCT/US2022/077182 WO2023056297A1 (en) 2021-09-28 2022-09-28 Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome

Publications (1)

Publication Number Publication Date
IL311710A true IL311710A (en) 2024-05-01

Family

ID=84360925

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311710A IL311710A (en) 2021-09-28 2022-09-28 Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome

Country Status (11)

Country Link
US (2) US20240383991A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408455A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024535431A (cg-RX-API-DMAC7.html)
KR (1) KR20240101563A9 (cg-RX-API-DMAC7.html)
AU (1) AU2022358509A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230926A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000881A1 (cg-RX-API-DMAC7.html)
IL (1) IL311710A (cg-RX-API-DMAC7.html)
MA (1) MA65537A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003954A (cg-RX-API-DMAC7.html)
WO (1) WO2023056297A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260217842A1 (en) * 2023-01-13 2026-07-30 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
KR20250162587A (ko) * 2023-03-28 2025-11-18 비엘라 바이오, 인크. 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3704158A1 (en) * 2017-11-03 2020-09-09 Novartis AG Anti-cd40 antibodies for use in treatment of sjögren's syndrome
KR102919125B1 (ko) * 2018-09-26 2026-01-27 비엘라 바이오, 인크. Cd40l 길항제 및 이의 용도

Also Published As

Publication number Publication date
MA65537A1 (fr) 2025-06-30
CL2024000881A1 (es) 2024-09-13
EP4408455A1 (en) 2024-08-07
US20260070997A1 (en) 2026-03-12
AU2022358509A1 (en) 2024-03-28
JP2024535431A (ja) 2024-09-30
WO2023056297A1 (en) 2023-04-06
MX2024003954A (es) 2024-04-24
CL2025000581A1 (es) 2025-07-11
CA3230926A1 (en) 2023-04-06
KR20240101563A (ko) 2024-07-02
US20240383991A1 (en) 2024-11-21
KR20240101563A9 (ko) 2025-12-10

Similar Documents

Publication Publication Date Title
IL282727A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HUE045137T2 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
EP3601285A4 (en) THERAPEUTIC AGENT FOR THE INHIBITION OF PHOSPHODIESTERASE AND ITS RELATED DISORDERS
DK3504210T3 (da) 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion
IL269083A (en) Methods for preventing and treating heart disease
IL281394A (en) Method and composition for preventing and treating atherosclerosis and related diseases
EP3728279A4 (en) GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISEASES
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
IL282273A (en) Urea derivatives for treating and/or preventing cancer
EP3966320A4 (en) Treatment and detection of inherited neuropathies and associated disorders
EP3615547A4 (en) TREATMENT AND PREVENTION OF KIDNEY DAMAGE
EP3558335A4 (en) INHIBITION OF CASPASE-1 AND ITS USES IN THE PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
IL310870A (en) Quinazoline compounds for treatment of disease
EP4041275A4 (en) TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY DAMAGE
EP4203954A4 (en) Glucosidase inhibitors for the treatment and prevention of pulmonary infections
KR20240101563A9 (ko) 쇼그렌 증후군의 치료 및 예방을 위한 cd40l-특이적 tn3-유래된 스캐폴드
EP4069847A4 (en) Treatment of lower airways disorders
IT201700109080A1 (it) Composizione per la prevenzione e/o il trattamento delle affezioni delle vie respiratorie
IL312885A (en) Nitroxoline for use in the treatment or prevention of flexiform neurofibroma
MA55467A (fr) Utilisations thérapeutiques de dulaglutide
SG11202008791UA (en) Agent for prevention and/or treatment of pseudomonas aeruginosa infection
EP4223303A4 (en) ANTIVIRAL AGENT FOR PREVENTING OR TREATING COVID-19 INFECTION
IL281447A (en) Methods and compositions for treating viral infections
DK4054582T3 (da) Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter